Home › Companies › Rhythm Pharmaceuticals, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Rhythm Pharmaceuticals, Inc.’s Form 8-K, filed June 25, 2026 (Item 5.07 on EDGAR). Page generated October 18, 2026.
Meeting of June 24, 2026: 4 items on Rhythm Pharmaceuticals, Inc.’s Form 8-K, filed June 25, 2026: 1 approved · 3 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025 2025-2026
Explore Rhythm Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Rhythm Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 25, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: David W. J. McGirr | 53,167,971 | -- | -- | 8,704,527 | 2,273,648 | 86% | Not verified | — |
| Elect Director: David P. Meeker, MD | 59,961,848 | -- | -- | 1,910,650 | 2,273,648 | 97% | Not verified | — |
| 2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 | 63,924,852 | 197,701 | 23,593 | -- | 0 | 99.6% | Not verified | — |
| 3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers | 50,368,659 | 11,467,157 | 36,682 | -- | 2,273,648 | 81% | Approved | — |
Source: Rhythm Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 25, 2026 — read the filing on EDGAR.
Each item below shows how the 316 asset managers that disclosed a Rhythm Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: Election of the Class III directors, each to serve for a three year term until the 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: David P. Meeker, M.D.
Rhythm Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David P. Meeker, MD”): 59,961,848 for, 1,910,650 withheld, per its Form 8-K filed June 25, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 83 asset managers below reported 26,706,633 for, 457,133 withheld, 17,581 abstained, 79 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,298,341 | 0 | 4 | 3,459 | For |
| PRIMECAP Odyssey Funds | 3,218,761 | 0 | 0 | 0 | For |
| BlackRock | 3,056,515 | 0 | 0 | 0 | For |
| Fidelity | 2,582,329 | 0 | 0 | 0 | For |
| Capital Group | 1,626,217 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,271,178 | 0 | 0 | 0 | For |
| Federated Hermes | 1,239,612 | 0 | 0 | 0 | For |
| State Street | 1,062,793 | 0 | 0 | 10 | For |
| JPMorgan | 1,051,685 | 0 | 0 | 0 | For |
| Charles Schwab | 527,140 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 437,490 | 0 | 0 | 0 | For |
| Putnam | 0 | 0 | 0 | 415,259 | Withhold |
| Columbia Threadneedle | 294,669 | 0 | 0 | 0 | For |
| Invesco | 289,357 | 0 | 0 | 0 | For |
| AllianceBernstein | 283,662 | 0 | 0 | 0 | For |
| Legg Mason | 279,705 | 0 | 0 | 0 | For |
| Loomis Sayles | 253,415 | 0 | 0 | 0 | For |
| Jackson National | 230,045 | 0 | 0 | 0 | For |
| Lord Abbett | 226,824 | 0 | 0 | 0 | For |
| Equitable | 208,076 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 196,524 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 160,640 | 0 | 0 | 0 | For |
| Voya | 152,881 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 141,534 | 0 | 0 | 0 | For |
| Goldman Sachs | 124,948 | 0 | 0 | 3,294 | For |
Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.
Combines 6 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Description as filed by funds: Election of the Class III directors, each to serve for a three year term until the 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: David W.J. McGirr
Rhythm Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David W. J. McGirr”): 53,167,971 for, 8,704,527 withheld, per its Form 8-K filed June 25, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 83 asset managers below reported 24,455,090 for, 2,025,206 withheld, 701,050 abstained, 79 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,298,324 | 0 | 21 | 3,459 | For |
| PRIMECAP Odyssey Funds | 3,218,761 | 0 | 0 | 0 | For |
| BlackRock | 3,056,515 | 0 | 0 | 0 | For |
| Fidelity | 2,582,329 | 0 | 0 | 0 | For |
| Capital Group | 1,626,217 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,271,178 | 0 | 0 | 0 | For |
| Federated Hermes | 1,239,612 | 0 | 0 | 0 | For |
| State Street | 1,053,968 | 0 | 0 | 8,835 | For |
| JPMorgan | 1,051,685 | 0 | 0 | 0 | For |
| Charles Schwab | 527,140 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 0 | 0 | 437,490 | 0 | Abstain |
| Putnam | 0 | 0 | 0 | 415,259 | Withhold |
| Columbia Threadneedle | 294,669 | 0 | 0 | 0 | For |
| Invesco | 289,357 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 283,662 | Withhold |
| Legg Mason | 275,593 | 0 | 0 | 4,112 | For |
| Loomis Sayles | 253,415 | 0 | 0 | 0 | For |
| Jackson National | 203,950 | 0 | 26,095 | 0 | Mixed |
| Lord Abbett | 0 | 0 | 0 | 226,824 | Withhold |
| Equitable | 79,391 | 0 | 0 | 128,685 | Mixed |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 196,524 | Withhold |
| JANUS INVESTMENT FUND | 160,640 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 0 | 152,881 | Withhold |
| Bridge Builder Trust | 44,584 | 0 | 96,950 | 0 | Mixed |
| Goldman Sachs | 113,058 | 0 | 0 | 15,184 | Mixed |
Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.
Combines 10 wordings of this item as funds reported it.
81% Approved · of votes cast
Description as filed by funds: Approval, on an advisory (non- binding) basis, of the compensation of the named executive officers of the Company.
Rhythm Pharmaceuticals, Inc.’s own tally for this item (“3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers”): 50,368,659 for, 11,467,157 against — passed, per its Form 8-K filed June 25, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Item 3 - Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.”
Support: 81% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,301,781 | 23 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,218,761 | 0 | 0 | 0 | For |
| BlackRock | 3,056,515 | 0 | 0 | 0 | For |
| Fidelity | 2,582,329 | 0 | 0 | 0 | For |
| Capital Group | 0 | 1,626,217 | 0 | 0 | Against |
| T. Rowe Price | 1,271,178 | 0 | 0 | 0 | For |
| Federated Hermes | 1,239,612 | 0 | 0 | 0 | For |
| State Street | 1,053,968 | 8,835 | 0 | 0 | For |
| JPMorgan | 1,051,685 | 0 | 0 | 0 | For |
| Charles Schwab | 527,140 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 0 | 437,490 | 0 | 0 | Against |
| Putnam | 0 | 415,259 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 294,669 | 0 | 0 | Against |
| Invesco | 0 | 289,357 | 0 | 0 | Against |
| AllianceBernstein | 283,662 | 0 | 0 | 0 | For |
| Legg Mason | 275,593 | 4,112 | 0 | 0 | For |
| Loomis Sayles | 253,415 | 0 | 0 | 0 | For |
| Jackson National | 230,045 | 0 | 0 | 0 | For |
| Lord Abbett | 226,824 | 0 | 0 | 0 | For |
| Equitable | 208,076 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 196,524 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 160,640 | 0 | 0 | 0 | For |
| Voya | 152,881 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 44,584 | 96,950 | 0 | 0 | Mixed |
| Goldman Sachs | 113,058 | 15,184 | 0 | 0 | Mixed |
Fund voting reports, all 83 managers: 23,202,800 for, 3,959,834 against, 18,712 abstained, 79 not voted. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 6,616,427 | 0 | 0 | 0 | For |
| BAKER BROS. ADVISORS LP | 5,604,483 | 0 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 3,406,249 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 0 | 3,055,872 | 0 | 0 | Against |
| BlackRock | 2,718,872 | 8,500 | 119 | 0 | For |
| State Street | 2,137,197 | 23,382 | 0 | 0 | For |
| T. Rowe Price | 1,881,923 | 0 | 0 | 0 | For |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 0 | 1,750,593 | 0 | 0 | Against |
| Fidelity | 1,614,643 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 1,505,179 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,412,746 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 0 | 1,410,524 | 0 | 0 | Against |
| Janus Henderson | 1,276,610 | 14,502 | 0 | 0 | For |
| Federated Hermes | 1,281,535 | 0 | 0 | 0 | For |
| Checkpoint Capital L.P. | 1,187,666 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 1,136,275 | 0 | 0 | 0 | For |
| AllianceBernstein | 899,340 | 0 | 0 | 0 | For |
| Citadel | 881,582 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0 | 655,644 | 0 | 0 | Against |
| Clearbridge Investments, LLC | 653,918 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 0 | 650,814 | 0 | 0 | Against |
| Putnam | 0 | 575,431 | 0 | 0 | Against |
| Charles Schwab | 532,245 | 0 | 0 | 0 | For |
| Vanguard | 512,767 | 1,896 | 0 | 0 | For |
| Woodline Partners LP | 482,080 | 0 | 0 | 0 | For |
Institutional-manager reports, all 260 managers: 39,244,139 for, 12,187,275 against, 4,046 abstained, 35,489 not voted. Showing the 25 largest; see all in the interactive database.
99.6% Majority: yes · of votes cast
Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Rhythm Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026”): 63,924,852 for, 197,701 against, per its Form 8-K filed June 25, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 83 asset managers below reported 27,162,603 for, 31 against, 18,712 abstained, 79 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,301,804 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,218,761 | 0 | 0 | 0 | For |
| BlackRock | 3,056,515 | 0 | 0 | 0 | For |
| Fidelity | 2,582,329 | 0 | 0 | 0 | For |
| Capital Group | 1,626,217 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,271,178 | 0 | 0 | 0 | For |
| Federated Hermes | 1,239,612 | 0 | 0 | 0 | For |
| State Street | 1,062,772 | 31 | 0 | 0 | For |
| JPMorgan | 1,051,685 | 0 | 0 | 0 | For |
| Charles Schwab | 527,140 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 437,490 | 0 | 0 | 0 | For |
| Putnam | 415,259 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 294,669 | 0 | 0 | 0 | For |
| Invesco | 289,357 | 0 | 0 | 0 | For |
| AllianceBernstein | 283,662 | 0 | 0 | 0 | For |
| Legg Mason | 279,705 | 0 | 0 | 0 | For |
| Loomis Sayles | 253,415 | 0 | 0 | 0 | For |
| Jackson National | 230,045 | 0 | 0 | 0 | For |
| Lord Abbett | 226,824 | 0 | 0 | 0 | For |
| Equitable | 208,076 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 196,524 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 160,640 | 0 | 0 | 0 | For |
| Voya | 152,881 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 141,534 | 0 | 0 | 0 | For |
| Goldman Sachs | 128,242 | 0 | 0 | 0 | For |
Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 68,445,084 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 9.21% |
| 2 | PRIMECAP Odyssey Funds | 4.70% |
| 3 | BlackRock | 4.47% |
| 4 | Fidelity | 3.77% |
| 5 | Capital Group | 2.38% |
| 6 | T. Rowe Price | 1.86% |
| 7 | Federated Hermes | 1.81% |
| 8 | State Street | 1.55% |
| 9 | JPMorgan | 1.54% |
| 10 | Charles Schwab | 0.77% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 9.67% |
| 2 | BAKER BROS. ADVISORS LP | 8.19% |
| 3 | PRIMECAP MANAGEMENT CO/CA/ | 4.98% |
| 4 | Polar Capital Holdings Plc | 4.46% |
| 5 | BlackRock | 3.98% |
| 6 | State Street | 3.16% |
| 7 | T. Rowe Price | 2.75% |
| 8 | WESTFIELD CAPITAL MANAGEMENT CO LP | 2.56% |
| 9 | Fidelity | 2.36% |
| 10 | PERCEPTIVE ADVISORS LLC | 2.20% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| RA Capital Management, L.P. | 9.74% | 13G |
| BlackRock | 9.11% | 13F |
| Vanguard Group | 9.07% | 13F |
| PRIMECAP MANAGEMENT CO/CA/ | 5.08% | 13G |
| State Street | 3.32% | 13F |
| Goldman Sachs | 2.87% | 13F |
| FMR (Fidelity) | 2.47% | 13F |
| T. Rowe Price | 2.42% | 13F |
| JPMorgan Chase | 2.27% | 13F |
| Citadel Advisors | 2.12% | 13F |
Percentages above are of 68,445,084 shares outstanding, as reported by Rhythm Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Rhythm Pharmaceuticals, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.
At Rhythm Pharmaceuticals, Inc.'s shareholder meeting held June 24, 2026, in the 2025-2026 proxy season, 316 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 1,679 separate fund positions. On the most widely held item on that ballot — Approval, on an advisory (non- binding) basis, of the compensation of the named executive… — Rhythm Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 81% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Rhythm Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 25, 2026.
Rhythm Pharmaceuticals, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.